Leukocyte Adhesion Deficiency Management Market

Leukocyte Adhesion Deficiency Management Market Size, Market Forecast and Outlook By FMI

Summary of the Leukocyte Adhesion Deficiency Management Market

• Demand and Growth Drivers
  • Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for severe LAD, creating concentrated demand at specialized transplant centers and tertiary care hospitals.
  • Gene therapy clinical programs targeting LAD type I are advancing through development, with potential to expand curative treatment options beyond stem cell transplantation.
  • Improved neonatal screening and genetic diagnostic capabilities are increasing the identified patient population, expanding the treated patient base for both curative and supportive therapies.
• Product and Segment View
  • Hematopoietic Stem Cell Transplantation is expected to hold 62.0% of the Treatment segment in 2026, reflecting clinical demand for curative transplant procedures.
  • Blood Test is expected to hold 52.6% of the Diagnosis segment in 2026, reflecting clinical demand for curative transplant procedures.
  • Curative Therapy is expected to hold 63.4% of the Therapy Approach segment in 2026, reflecting clinical demand for curative transplant procedures.
• Geography and Competitive Outlook
  • With the help of cutting-edge transplant infrastructure, gene therapy trial programs, and investments in rare illness treatment, the USA is predicted to lead growth at 6.9%.
  • Japan comes in second at 6.8%, thanks to programs for treating rare diseases and sophisticated healthcare infrastructure.
  • Rocket Pharmaceuticals and other well-known companies compete in the gene therapy pipeline and transplant technology.
• Analyst Opinion
  • As gene therapy initiatives move closer to regulatory submission, the market for leukocyte adhesion deficiency management is poised for change, potentially increasing access to curative treatments outside of HSCT.
  • The rate of early LAD detection is anticipated to rise with improved newborn screening and genetic diagnostics, allowing for earlier treatment initiation and improved clinical results.
  • Demand for supportive treatment, such as prophylactic immunoglobulin and antibacterial therapy, offers a steady stream of income to supplement the sporadic expenses associated with transplant procedures.
  • As the therapeutic landscape changes, businesses with knowledge of rare diseases and the capacity to manufacture gene therapy are well-positioned to take the lead in market development.

Key Takeaways, Market Size, and Forecast

• The leukocyte adhesion deficiency management market is projected to grow from USD 9.8 billion in 2026 to USD 18.7 billion by 2036, at a CAGR of 6.7%.
• The market was valued at USD 9.18 billion in 2025.
• By 2036, the market is expected to reach approximately USD 18.73 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 6.7%.
• The market is expected to create an incremental opportunity of USD 8.94 billion between 2026 and 2036.
• In 2026, hematopoietic stem cell transplantation is expected to account for 62.0% of the treatment segment, driven by clinical demand for curative transplant procedures and supportive therapy in diagnosed LAD patients.
• The USA (6.9%) and Japan (6.8%) are among the fastest-growing markets globally.

Leukocyte Adhesion Deficiency Management Market Definition

The Leukocyte Adhesion Deficiency Management Market covers therapeutic products and procedures used to treat LAD, including hematopoietic stem cell transplantation, immunoglobulin therapy, antimicrobial prophylaxis, gene therapy, and supportive care for all LAD subtypes.

Leukocyte Adhesion Deficiency Management Market Inclusions

Market scope covers all commercially available products and services categorized by treatment (Treatment, Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors), diagnosis (Diagnosis, Blood Test, Genetic Testing), therapy approach (Therapy Approach, Curative Therapy, Supportive Therapy, Preventive Therapy), disease severity (Disease Severity, Severe Leukocyte Adhesion Deficiency, Moderate Leukocyte Adhesion Deficiency, Mild Leukocyte Adhesion Deficiency, Recurrent Infection Episodes), end users (End Users, Hospitals, Specialty Clinics, Others), distribution channel (Distribution Channel, Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies, Direct Hospital Procurement). Revenue coverage spans the 2026 to 2036 forecast period.

Leukocyte Adhesion Deficiency Management Market Exclusions

The scope does not include general immunology products not specifically used for LAD treatment, diagnostic equipment and laboratory services, or research-use-only reagents not intended for clinical application.

Leukocyte Adhesion Deficiency Management Market Research Methodology

• Primary Research: FMI analysts conducted interviews with specialist dermatologists, immunologists, transplant physicians, hospital pharmacy managers, and rare disease treatment program coordinators in key markets.
• Desk research: Integrated information from treatment guideline publications, rare disease patient registries, pharmaceutical regulatory filings, and clinical trial registries.
• Market sizing and forecasting: Adoption velocity modeling, cross-validation against industry benchmarks, and bottom-up aggregation across sectors and geographies.
• Data validation: Cross-checked quarterly against clinical trial data, patient registry updates, and pharmaceutical manufacturer disclosures.

Why is the Leukocyte Adhesion Deficiency Management Market Growing?

• Allogeneic transplants from matched sibling donors are the preferred method when available, and HSCT is the proven curative treatment for severe LAD, accounting for {SEG_SHARE} of the treatment segment.
• The main pipeline opportunity is represented by gene therapy development programs aimed at CD18 gene repair in LAD type I, with clinical studies underway in the US and the EU.
• With 6.9% growth, the USA leads the world thanks to investments in rare illness treatment, gene therapy trial studies, and sophisticated transplant infrastructure.

As therapeutic options for this uncommon primary immunodeficiency illness increase and diagnostic skills improve, the market for leukocyte adhesion deficiency management is expanding. Since hematopoietic stem cell transplantation is still the only therapeutic option for severe LAD, it makes up 62.0% of the treatment segment. Patients awaiting transplantation or those with intermediate illness severity are served by preventive infection management and supportive antimicrobial therapy, whereas curative therapy accounts for 62.0% of the therapy approach segment. The concentration of treatment spending on individuals with the most urgent clinical need is reflected in the fact that severe LAD makes up 62.0% of the disease severity segment. At 62.0%, blood tests-such as flow cytometry and total blood counts-lead the diagnostic category. Genetic testing and molecular diagnostics, on the other hand, offer a conclusive diagnosis by identifying mutations in the ITGB2 gene. Tertiary care hospitals and transplant centers are the main treatment facilities, accounting for 62.0% of end-user demand. In line with the inpatient treatment scenario for HSCT and acute infection care, hospital pharmacies account for 62.0% of distribution. Patients on long-term preventive immunoglobulin therapy and antibiotic regimens are served by specialty pharmacies. Because LAD is an uncommon disease, treatment is concentrated at a small number of specialized immunology facilities, which results in a concentrated procurement pattern.

Market Segmentation Analysis

• Hematopoietic Stem Cell Transplantation holds 62.0% of the Treatment segment in 2026.
• Blood Test accounts for 52.6% of the Diagnosis segment.

The Leukocyte Adhesion Deficiency Management Market is organized across 6 segmentation dimensions: Treatment, Diagnosis, Therapy Approach, Disease Severity, End Users, Distribution Channel. Procurement patterns reflect clinical treatment protocols, diagnostic pathways, and institutional procurement patterns at specialist treatment centers.

Insights into the Hematopoietic Stem Cell Transplantation Treatment Segment

In 2026, Hematopoietic Stem Cell Transplantation is expected to account for 62.0% of the Treatment segment. Key sub-categories include Allogeneic Transplant, Matched Sibling Donor, each serving specific application requirements.

Hematopoietic Stem Cell Transplantation holds 62.0% of the segment, contributing additional demand through specialized applications. Recombinant Human Interferon-gamma Treatment is also contributing to segment growth as the market diversifies across product categories and application requirements.

Insights into the Curative Therapy Approach Segment

It is anticipated that Curative Therapy would make up 63.4% of the Therapy Approach market in 2026. Hematopoietic stem cell transplantation is one of the important subcategories, each fulfilling certain application needs. With specialized applications, curative therapy accounts for 63.4% of the market. As the market diversifies across product categories and application requirements, supportive therapy is also helping to drive segment growth.

Leukocyte Adhesion Deficiency Management Market Drivers, Restraints, and Opportunities

• HSCT as the Curative Standard: Allogeneic HSCT from matched sibling donors remains the preferred curative treatment for severe LAD.
• Clinical programs targeting CD18 gene correction using lentiviral and AAV vectors are advancing for LAD type I.
• Advances in neonatal screening, flow cytometry, and genetic testing are increasing the rate of LAD diagnosis.

The Leukocyte Adhesion Deficiency Management Market is shaped by clinical treatment requirements, diagnostic improvement, pharmaceutical pipeline development, and specialty distribution access. Growth reflects the balance between clinical or commercial demand drivers and adoption barriers.

HSCT as the Curative Standard

For severe LAD, allogeneic HSCT from matched sibling donors is still the recommended course of treatment. The usefulness of this strategy is limited by donor availability issues and transplant-related morbidity, which keeps patients without appropriate donors in need of supportive care and alternate treatment modalities.

Gene Therapy Pipeline Development

For LAD type I, clinical initiatives focusing on CD18 gene repair with lentiviral and AAV vectors are progressing. If gene therapy is developed successfully, individuals without matched donors may have greater access to curative treatment, and long-term medical expenses related to chronic supportive therapy may be decreased.

Diagnostic Improvement and Patient Identification

The rate of LAD diagnosis is rising thanks to developments in genetic testing, flow cytometry, and newborn screening. Early detection improves clinical outcomes by enabling prompt treatment planning, including the start of preventive therapy and the donor search.

Supportive Care and Infection Management

Immunoglobulin replacement, infection control, and continuous antimicrobial prophylaxis are necessary for patients with moderate LAD or those awaiting transplantation. The episodic cost of transplant procedures is supplemented by the ongoing pharmaceutical demand created by this supportive care component.

Analysis of Leukocyte Adhesion Deficiency Management Market By Key Countries

Source: FMI analysis based on primary research and proprietary forecasting model

• USA at 6.9% is supported by advanced transplant infrastructure, gene therapy clinical programs, and rare disease treatment investment.
• Japan at 6.8% is supported by advanced healthcare infrastructure and rare disease treatment programs.
• EU at 6.7% is supported by orphan drug regulatory frameworks and rare disease treatment center networks.
• South Korea at 6.6% is supported by growing rare disease treatment capabilities and biosimilar development.

The global Leukocyte Adhesion Deficiency Management Market is projected to expand at a CAGR of 6.7% from 2026 to 2036. The analysis covers more than 30 countries, with distinct growth profiles based on clinical treatment requirements, diagnostic improvement, pharmaceutical pipeline development, and specialty distribution access.

Demand Outlook for Leukocyte Adhesion Deficiency Management Market in the United States

The United States is projected to grow at 6.9% through 2036. Advanced transplant infrastructure, gene therapy clinical programs, and rare disease treatment investment are the primary factors shaping demand.

• Advanced transplant infrastructure supports demand growth.
• Gene therapy clinical programs supports demand growth.
• Rare disease treatment investment supports demand growth.

Future Outlook for Leukocyte Adhesion Deficiency Management Market in the United Kingdom

The United Kingdom is projected to grow at 6.5% through 2036. NHS specialist immunology services and clinical trial participation are the primary factors shaping demand.

• NHS specialist immunology services and clinical trial participation supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks are supporting market development.

Opportunity Analysis of Leukocyte Adhesion Deficiency Management Market in Japan

Japan is projected to grow at 6.8% through 2036. Advanced healthcare infrastructure and rare disease treatment programs are the primary factors shaping demand.

• Advanced healthcare infrastructure and rare disease treatment programs supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks are supporting market development.

In-depth Analysis of Leukocyte Adhesion Deficiency Management Market in the European Union

The European Union is projected to grow at 6.7% through 2036. Orphan drug regulatory frameworks and rare disease treatment center networks are the primary factors shaping demand.

• Orphan drug regulatory frameworks and rare disease treatment center networks supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks are supporting market development.

Sales Analysis of Leukocyte Adhesion Deficiency Management Market in South Korea

South Korea is projected to grow at 6.6% through 2036. Growing rare disease treatment capabilities and biosimilar development are the primary factors shaping demand.

• Growing rare disease treatment capabilities and biosimilar development supports demand growth.
• Expanding demand base contributes to market expansion.
• Regulatory and institutional frameworks are supporting market development.

Competitive Landscape and Strategic Positioning

• Based on transplant technology and the gene therapy pipeline, Rocket Pharmaceuticals is at the forefront.
• The pipeline for gene therapy, transplant technology, knowledge of uncommon diseases, and geographic reach are areas where established players compete.
• New competitors are concentrating on narrow market positioning and specialized skills.

With its well-established gene therapy pipeline and transplant technologies, Rocket Pharmaceuticals maintains a dominant market position. Orchard Therapeutics' experience in rare diseases and related skills help them maintain a solid position.Avrobio, Inc., Magenta Therapeutics, and Lonza Group compete based on their geographic reach and specific skills. These businesses use customized product and service strategies to cater to certain market segments.Investments in the gene therapy pipeline, regulatory compliance, and distribution infrastructure are necessary for market launch. Customer relationships and track records that take years to build are advantageous to established businesses.

Key Companies in the Leukocyte Adhesion Deficiency Management Market

Key global companies leading the leukocyte adhesion deficiency management market include:

• Rocket Pharmaceuticals, Orchard Therapeutics, Avrobio, Inc., Magenta Therapeutics are the established market leaders with broad capabilities across gene therapy pipeline and transplant technology.
• Lonza Group, Bluebird Bio, Be The Match BioTherapies have built regional positions through specialized capabilities and targeted market strategies.
• CSL Behring, Gilead Sciences, Novartis Gene Therapies are entering through niche specialization and technology-driven differentiation.

Competitive Benchmarking: Leukocyte Adhesion Deficiency Management Market

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Leukocyte Adhesion Deficiency Management Market

• In 2025, Rocket Pharmaceuticals streamlined its operational focus to prioritize the regulatory and commercial preparation of its gene therapy, KRESLADI™, for Leukocyte Adhesion Deficiency (LAD-I).
• Throughout 2025, the LAD-I management landscape shifted focus from traditional hematopoietic stem cell transplantation toward the integration of novel gene therapy solutions.

Key Players in the Leukocyte Adhesion Deficiency Management Market:

Major Global Players:

• Rocket Pharmaceuticals
• Orchard Therapeutics
• Avrobio, Inc.
• Magenta Therapeutics
• Lonza Group
• Bluebird Bio
• Be The Match BioTherapies

Emerging Players/Startups

• CSL Behring
• Gilead Sciences
• Novartis Gene Therapies

Report Scope and Coverage

Leukocyte Adhesion Deficiency Management Market Segmentation

Leukocyte Adhesion Deficiency Management Market Market Segmented by Treatment:

• Hematopoietic Stem Cell Transplantation
  • Allogeneic Transplant
  • Matched Sibling Donor
• Recombinant Human Interferon-gamma Treatment
  • Standard Therapy
• Prophylactic Immunoglobulin Therapy
  • Intravenous Immunoglobulin
  • Subcutaneous Immunoglobulin
• Antimicrobial Therapy
  • Antibiotic Therapy
  • Antifungal Therapy
• Prophylactic Therapy
  • Infection Prevention Protocols
• Fucose Supplementation
  • Oral Supplementation
• Monoclonal Antibodies
  • Targeted Immunotherapy
• Coagulation Factors
  • Factor Replacement Therapy

Leukocyte Adhesion Deficiency Management Market Market Segmented by Diagnosis:

• Blood Test
  • Complete Blood Count
  • Flow Cytometry
• Genetic Testing
  • Molecular Diagnostics
  • Gene Sequencing

Leukocyte Adhesion Deficiency Management Market Market Segmented by Therapy Approach:

• Curative Therapy
  • Hematopoietic Stem Cell Transplantation
• Supportive Therapy
  • Antimicrobial Therapy
  • Immunoglobulin Therapy
• Preventive Therapy
  • Prophylactic Infection Control

Leukocyte Adhesion Deficiency Management Market Market Segmented by Disease Severity:

• Severe Leukocyte Adhesion Deficiency
  • Classical LAD Type I
  • Classical LAD Type II
• Moderate Leukocyte Adhesion Deficiency
• Mild Leukocyte Adhesion Deficiency
• Recurrent Infection Episodes
  • Acute Infection Management
  • Chronic Infection Management

Leukocyte Adhesion Deficiency Management Market Market Segmented by End Users:

• Hospitals
  • Tertiary Care Hospitals
  • Transplant Centers
• Specialty Clinics
  • Immunology Clinics
• Others

Leukocyte Adhesion Deficiency Management Market Market Segmented by Distribution Channel:

• Hospital Pharmacies
  • Inpatient Dispensing
• Specialty Pharmacies
  • Rare Disease Pharmacies
• Online Pharmacies
  • E-Pharmacy Platforms
• Direct Hospital Procurement
  • Tender Based Supply

Leukocyte Adhesion Deficiency Management Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• National Institutes of Health. (2024). NIH Rare Diseases Clinical Research Network: Primary Immunodeficiency Research Programs. NIH.
• European Medicines Agency. (2024). EMA Orphan Medicinal Products: Regulatory Framework for Rare Disease Treatments. EMA.
• USA Food and Drug Administration. (2024). FDA Office of Orphan Products Development: Gene Therapy Guidance for Rare Diseases. FDA.
• World Health Organization. (2025). WHO Classification of Primary Immunodeficiency Diseases. WHO.
• European Society for Immunodeficiencies. (2024). ESID Registry: Clinical Data on Leukocyte Adhesion Deficiency. ESID.
• International Patient Organisation for Primary Immunodeficiencies. (2024). IPOPI Global Survey on Access to Treatment for Primary Immunodeficiencies. IPOPI.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the size of the market and revenue from 2026 to 2036.
• Segmentation by Treatment, Diagnosis, Therapy Approach, Disease Severity, End Users, Distribution Channel, and region.
• Insights about more than 30 markets across regions.
• Technology and treatment landscape analysis.
• Assessment of the competitive landscape.
• Finding investment opportunities across segments and regions.
• Supply chain and distribution analysis.
• Delivery of data in PDF and Excel formats.